Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

Exercise During Active Surveillance for Prostate Cancer (ERASE)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT03203460
Recruitment Status : Recruiting
First Posted : June 29, 2017
Last Update Posted : March 25, 2019
Sponsor:
Information provided by (Responsible Party):
Kerry Courneya, University of Alberta

Brief Summary:
The broad goal of the Exercise During Active Surveillance for Prostate Cancer (ERASE) trial is to examine the effects of exercise in prostate cancer patients undergoing active surveillance.

Condition or disease Intervention/treatment Phase
Prostate Cancer Behavioral: High-intensity aerobic interval training (HIIT) Not Applicable

Detailed Description:
The ERASE Trial will be a phase II randomized controlled trial. A total of 66 men with low- or intermediate-grade clinically localized prostate cancer undergoing active surveillance will be randomized to either a 12-week of supervised high-intensity aerobic interval training or usual care. The primary outcome will be peak oxygen consumption (VO2peak) as a measure of physical fitness. The secondary outcomes include tumour-related biomarkers, fear of cancer progression, quality of life, and psychological distress. Exploratory outcomes will include indicators of cancer progression including prostate-specific antigen. Based on this sample size, our study has 80% power with a two-tailed alpha <0.05 to detect a clinically meaningful effect of 3.5 ml/kg/min on our primary outcome of VO2max. This power will also be sufficient for detecting differences in our secondary biomarkers and patient-reported outcomes if the effects are at least moderate (i.e., a standardized effect size of d=0.60).

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 66 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Single (Outcomes Assessor)
Masking Description: The outcome assessor will be blinded to group assignment for the primary outcome of natural killer cell cytotoxic activity and the secondary outcomes of other circulating biomarkers.
Primary Purpose: Supportive Care
Official Title: A Phase II Randomized Controlled Trial of Exercise in Prostate Cancer Patients Undergoing Active Surveillance
Actual Study Start Date : July 1, 2018
Estimated Primary Completion Date : December 30, 2019
Estimated Study Completion Date : April 30, 2020

Resource links provided by the National Library of Medicine


Arm Intervention/treatment
Experimental: Exercise Group
Supervised high-intensity aerobic interval training (HIIT) during active surveillance
Behavioral: High-intensity aerobic interval training (HIIT)
A 12-week, supervised, HIIT aerobic exercise program consisting of alternating vigorous- and low-intensity intervals

No Intervention: Usual Care Group
The usual care group will be provided with standard active surveillance medical care.



Primary Outcome Measures :
  1. Changes of Peak Oxygen Consumption (VO2peak) [ Time Frame: At baseline and 12-week (postintervention) ]
    VO2peak is a measure of cardiopulmonary fitness and a powerful surrogate outcome for cancer-specific and overall survival. VO2peak will be defined as the highest oxygen-uptake value recorded during the test and quantified where participants reach a plateau in oxygen consumption, which will be expressed as relative to body mass (i.e., ml O2·kg-1·min-1).


Secondary Outcome Measures :
  1. Changes of Natural Killer Cell Cytotoxic Activity (NKCA) and Counts [ Time Frame: At baseline and 12-week (postintervention) ]
    NKCA significantly contributes to the regulation of tumour suppression in response to exercise and it has been demonstrated to have a diagnostic value in patients with cancer. NK cell activities are assessed using blood analysis as the total number of circulating NK cells and their cytotoxic activity. NK cell counts and NKCA will be measured using the phenotypic markers of NK cells (CD3-CD16+CD56+). NKCA will be expressed as the percentage of target cells killed by a sample of 100,000 peripheral blood mononuclear cells at the effector-to-target ratios of 5:1, 20:1, 40:1, and 100:1.

  2. Changes of Immune-Related Phenotype [ Time Frame: At baseline and 12-week (postintervention) ]
    Immune-related phenotypic markers, including CD3, CD16, CD56, and CD107 (on the frozen) and CD4, CD8, CD20, CD25, CD11, CD45RA, CD45RO, CD16, CD56, CD107 activation (fresh on whole blood), will be assessed using blood samples.

  3. Changes of Prostate-Specific Antigen (PSA) [ Time Frame: At baseline, 12-week (postintervention) ]
    PSA will be assessed using blood samples.

  4. Changes of Complete Blood Count with Differential (CBCD) [ Time Frame: At baseline and 12-week (postintervention) ]
    CBCD, including RBC, WBC, HGB, HCT, PLT, LYMPH, BASO, EOS, MONO, NEUT, will be assessed using blood samples.

  5. Changes of Insulin [ Time Frame: At baseline and 12-week (postintervention) ]
    Fasting insulin levels will be assessed using blood samples.

  6. Changes of Fasting Glucose [ Time Frame: At Baseline and 12-week postintervention ]
    Fasting glucose levels will be assessed using blood samples.

  7. Changes of HbA1c [ Time Frame: At Baseline and 12-week postintervention ]
    HbA1c will be assessed using using blood samples.

  8. Changes of Insulin-like Growth Factor (IGF)-axis [ Time Frame: At baseline and 12-week (postintervention) ]
    IGF-axis, including circulating IGF-1 and IGF binding protein(IGFBP)-3, will be assessed using blood samples.

  9. Changes of Pro-Inflammatory Cytokines [ Time Frame: At baseline and 12-week (postintervention) ]
    Pro-inflammatory cytokines, including IFN-γ, IL-1β, IL-2, IL-4, IL-6, IL-8, IL-10, IL-12p70, IL-13, and TNF-α, will be assessed.

  10. Changes of High-Sensitivity C-Reactive Protein (hs-CRP) [ Time Frame: At Baseline and 12-week postintervention ]
    hs-CRP will be assessed using blood samples.

  11. Changes of Adiponectin [ Time Frame: At Baseline and 12-week postintervention ]
    Adiponectin will be assessed using blood samples.

  12. Physical Function [ Time Frame: At Baseline and 12-week postintervention ]
    Physical function, consisting of strength, flexibility, and agility components, will be assessed by the Senior's Fitness Test (SFT).

  13. Health-Related Quality of Life [ Time Frame: At baseline, 12-week (postintervention), 6-month, and 12-month ]
    Health-related quality of life will be assessed using the European Organization for Research and Treatment of Cancer- Quality of Life Questionnaire (EORTC-QLQ) - C30 questionnaire.

  14. Prostate Cancer-Specific Quality of Life [ Time Frame: At baseline, 12-week (postintervention), 6-month, and 12-month ]
    Prostate cancer-specific quality of life will be assessed using the Expanded Prostate Cancer Index Composite-26 (EPIC-26) questionnaire.

  15. Fear of Cancer Progression [ Time Frame: At baseline, 12-week (postintervention), 6-month, and 12-month ]
    Fear of cancer progression will be assessed using the Fear of Cancer Recurrence Inventory (FCRI) questionnaire.

  16. Cancer Worry [ Time Frame: At baseline, 12-week (postintervention), 6-month, and 12-month ]
    Cancer worry will be assessed using the Cancer Worry Scale (CWS) questionnaire.

  17. General Anxiety [ Time Frame: At baseline, 12-week (postintervention), 6-month, and 12-month ]
    General anxiety will be assessed using the Anxiety (general): Spielberger State-Trait Anxiety Inventory (STAI) questionnaire.

  18. Prostate Cancer-Specific Anxiety [ Time Frame: At baseline, 12-week (postintervention), 6-month, and 12-month ]
    Prostate cancer-specific anxiety will be assessed using the Memorial Anxiety Scale for Prostate Cancer (MAX-PC) questionnaire.

  19. Depression [ Time Frame: At baseline, 12-week (postintervention), 6-month, and 12-month ]
    Depression will be assessed using the Epidemiologic Studies Depression Scale (CES-D) questionnaire.

  20. Perceived Stress [ Time Frame: At baseline, 12-week (postintervention), 6-month, and 12-month ]
    Perceived stress will be assessed using the Perceived Stress Scale (PSS) questionnaire.

  21. Self-esteem [ Time Frame: At baseline, 12-week (postintervention), 6-month, and 12-month ]
    Self-esteem will be assessed using the Rosenberg Self-Esteem Scale (RSES) questionnaire.

  22. Fatigue [ Time Frame: At baseline, 12-week (postintervention), 6-month, and 12-month ]
    Fatigue will be assessed using the Functional Assessment of Cancer Therapy- Fatigue (FACT-F) questionnaire.

  23. Physical Activity Level [ Time Frame: At baseline, 12-week (postintervention), 6-month, and 12-month ]
    Physical activity level, consisting of light-, moderate-, and vigorous aerobic exercise and resistance exercise, will be assessed using the Godin Leisure-Time Exercise Questionnaire (GLTEQ).

  24. Exercise Motivation [ Time Frame: At baseline, 12-week (postintervention), 6-month, and 12-month ]
    Exercise motivation, consisting of Theory of Planned Behaviour (TPB) constructs (instrumental and affective attitudes, subjective norms, intention and perceived behavioral control), will be assessed using questionnaire.

  25. Body composition [ Time Frame: At baseline and 12-week (postintervention) ]
    Body composition, including body weight and waist- and hip-circumferences, will be assessed using weight scales and a tape measure.



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   Male
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • ≥18 years of age
  • diagnosed with low or favorable intermediate grade localized PCa defined as PSA less than 10, Gleason Score 3+3 or 3+4 with low volume, and digital rectal examination (DRE) of T1C or T2A
  • initiating or continuing active surveillance with no plans for treatment for prostate cancer in the next 6 months (e.g., radical prostatectomy, radiotherapy, or androgen deprivation therapy)
  • screened for medical clearance for exercise testing and participation in vigorous aerobic exercise
  • residing in a commutable area near Edmonton, Alberta
  • willing to commute to the Behavioural Medicine Fitness Centre three times per week to attend a 12-week supervised high-intensity aerobic interval exercise program

Exclusion Criteria:

  • having comorbidities or uncontrolled medical conditions that their referred clinicians indicate as inappropriate to participate in exercise (e.g., known cardiac disease or uncontrolled hypertension)
  • having contraindications for cardiopulmonary stress and/or physical fitness tests
  • currently participating in a structured, vigorous exercise program.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03203460


Contacts
Layout table for location contacts
Contact: Dong-Woo Kang 780-492-8246 dongwoo.kang@ualberta.ca

Locations
Layout table for location information
Canada, Alberta
University of Alberta Recruiting
Edmonton, Alberta, Canada, T6G2H9
Contact: Dong-Woo Kang, PhD Candidate    780-492-8246    dongwoo.kang@ualberta.ca   
Sponsors and Collaborators
University of Alberta
Investigators
Layout table for investigator information
Principal Investigator: Kerry S Courneya, PhD University of Alberta

Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
Layout table for additonal information
Responsible Party: Kerry Courneya, Professor, University of Alberta
ClinicalTrials.gov Identifier: NCT03203460     History of Changes
Other Study ID Numbers: HREBA.CC-17-0248
First Posted: June 29, 2017    Key Record Dates
Last Update Posted: March 25, 2019
Last Verified: March 2019
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
Keywords provided by Kerry Courneya, University of Alberta:
Prostate Cancer
Active Surveillance
Exercise
High-Intensity Interval Training
Randomized Controlled Trial
Additional relevant MeSH terms:
Layout table for MeSH terms
Prostatic Neoplasms
Genital Neoplasms, Male
Urogenital Neoplasms
Neoplasms by Site
Neoplasms
Genital Diseases, Male
Prostatic Diseases